

Report from the Roundtable: Progress and Opportunities in the Managed Care of Dementia

This supplement to *The American Journal of Managed Care* will provide current information on dementia and highlight best practices in managed care decision-making, including coverage policy, risk assessment and management, and patient health outcomes.

■ Faculty

Valerie T. Cotter, MSN, CRNP, FAANP

Program Director, Adult Health & Gerontology
Nurse Practitioner Programs
School of Nursing
University of Pennsylvania
Philadelphia, Pennsylvania

Lori A. Daiello, PharmD, BCPP, FASCP

Geriatric Psychopharmacology Specialist
Pharmacotherapy Solutions
Providence, Rhode Island

Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD

Founding Executive Director
Health Policy Institute
University of the Sciences in Philadelphia
Philadelphia, Pennsylvania

■ Faculty Disclosures

These participants report relationships with the following pharmaceutical companies:

Lori A. Daiello, PharmD, BCPP, FASCP

Advisory board:

Abbott
Eli Lilly
Forest
Pfizer

Speakers' bureau:

Abbott
Eli Lilly
Forest

Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD

Editorial support:

Eisai
Novartis
Wyeth

Speakers' bureau:

Eisai
Forest
Pfizer
sanofi-aventis

Valerie T. Cotter, MSN, CRNP, FAANP, has no financial relationships to disclose.

The planning committee members, **Tara Herrmann, PhD**, and **Greselda Butler**, have no financial relationships to disclose.

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by pharmaceutical companies disclose any real or apparent conflicts of interest.

STAFF DISCLOSURES

The employees of MEC have no financial relationships to disclose.

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Princeton, New Jersey.

Report from the Roundtable: Progress and Opportunities in the Managed Care of Dementia

Purpose Statement

This educational activity will provide current information on dementia and highlight best practices in managed care decision-making, including coverage policy, risk assessment and management, and patient health outcomes.

TARGET AUDIENCE

Long-term care medical directors, consultant pharmacists, managed care stakeholders, and other long-term care practitioners who are involved in the clinical decision-making and delivery of care to the geriatric population.

EDUCATIONAL OBJECTIVES

Participants who read the supplement and complete the posttest should be better able to:

- Critically evaluate the role of antidementia medications and nonpharmacologic interventions in the managed care of dementia.
- Recognize and address potential polypharmacy-related and drug interaction issues of long-term care patients with dementia.
- Formulate effective risk assessment and management strategies in long-term dementia care.
- Identify risk factors associated with antipsychotic treatment for behavioral symptoms of dementia.

ACCREDITATION AND CREDIT DESIGNATION STATEMENT(S)

This activity is jointly sponsored by Medical Education Collaborative, Inc (MEC) and Emeritus Educational Sciences. MEC is a nonprofit organization that has been certifying quality educational activities since 1988.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of MEC and Emeritus Educational Sciences.

MEC is accredited by the ACCME to provide continuing medical education for physicians.

MEC designates this educational activity for a maximum of 1.0 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.



Pharmacy continuing education credit will be provided through MEC. MEC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This program is approved for 1.0 contact hour (0.1 CEU) of continuing education. ACPE Universal Program #815-999-07-064-H01-P.

To receive credit, participants must read the entire activity, complete the posttest, and submit a credit application and evaluation form. A minimum score of 70% is required. Statements of credit will be mailed within 6 to 8 weeks of completing the activity.

Release Date: December 2007.

Expiration Date: December 31, 2008.

This activity is supported by an educational grant from **Forest Pharmaceuticals, Inc.**

This activity contains information on unlabeled or investigational use of drug therapies that have not been approved by the US Food and Drug Administration.



The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.